CO2017002506A2 - Nuevos activadores de la guanilato ciclasa soluble y su uso - Google Patents
Nuevos activadores de la guanilato ciclasa soluble y su usoInfo
- Publication number
- CO2017002506A2 CO2017002506A2 CONC2017/0002506A CO2017002506A CO2017002506A2 CO 2017002506 A2 CO2017002506 A2 CO 2017002506A2 CO 2017002506 A CO2017002506 A CO 2017002506A CO 2017002506 A2 CO2017002506 A2 CO 2017002506A2
- Authority
- CO
- Colombia
- Prior art keywords
- guanylate cyclase
- soluble guanylate
- new activators
- activators
- pharmaceutical compositions
- Prior art date
Links
- 102000007637 Soluble Guanylyl Cyclase Human genes 0.000 title abstract 2
- 108010007205 Soluble Guanylyl Cyclase Proteins 0.000 title abstract 2
- 239000012190 activator Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 241001465754 Metazoa Species 0.000 abstract 1
- 239000003119 guanylate cyclase activator Substances 0.000 abstract 1
- 230000004410 intraocular pressure Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 241000894007 species Species 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
Abstract
La invención se refiere a activadores de la guanilato ciclasa soluble y su uso en composiciones farmacéuticas, principalmente composiciones oftálmicas administradas por vía tópica. Las composiciones farmacéuticas son útiles para reducir la presión intraocular en los animales de las especies de mamíferos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462052537P | 2014-09-19 | 2014-09-19 | |
| PCT/IB2015/057219 WO2016042536A1 (en) | 2014-09-19 | 2015-09-18 | Novel soluble guanylate cyclase activators and their use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2017002506A2 true CO2017002506A2 (es) | 2017-07-28 |
Family
ID=54238488
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2017/0002506A CO2017002506A2 (es) | 2014-09-19 | 2017-03-16 | Nuevos activadores de la guanilato ciclasa soluble y su uso |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US9938260B2 (es) |
| EP (1) | EP3194384A1 (es) |
| JP (3) | JP6678656B2 (es) |
| KR (1) | KR20170054508A (es) |
| CN (1) | CN106687456B (es) |
| AU (1) | AU2015319724B2 (es) |
| BR (1) | BR112017005660A2 (es) |
| CA (1) | CA2961745A1 (es) |
| CL (1) | CL2017000640A1 (es) |
| CO (1) | CO2017002506A2 (es) |
| CR (1) | CR20170102A (es) |
| DO (1) | DOP2017000073A (es) |
| EA (1) | EA033697B1 (es) |
| IL (1) | IL251094A0 (es) |
| MA (1) | MA40583A (es) |
| MX (1) | MX2017003621A (es) |
| PE (1) | PE20170937A1 (es) |
| PH (1) | PH12017500481A1 (es) |
| SG (1) | SG11201701915TA (es) |
| WO (1) | WO2016042536A1 (es) |
| ZA (1) | ZA201701835B (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI3406609T3 (fi) | 2014-02-06 | 2024-09-10 | Nxera Pharma Uk Ltd | Bisyklisiä atsayhdisteitä muskariinireseptorin agonisteina |
| CN107001331A (zh) | 2014-09-19 | 2017-08-01 | 拜耳制药股份公司 | 作为bub1抑制剂的苄基取代的吲唑 |
| JP6678656B2 (ja) * | 2014-09-19 | 2020-04-08 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | 新規な可溶性グアニル酸シクラーゼ活性剤およびそれらの使用 |
| CA3039735A1 (en) | 2016-10-11 | 2018-04-19 | Bayer Pharma Aktiengesellschaft | Combination containing sgc activators and mineralocorticoid receptor antagonists |
| WO2019081456A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT |
| EP3498298A1 (en) | 2017-12-15 | 2019-06-19 | Bayer AG | The use of sgc stimulators and sgc activators alone or in combination with pde5 inhibitors for the treatment of bone disorders including osteogenesis imperfecta (oi) |
| CN112055584A (zh) | 2018-04-30 | 2020-12-08 | 拜耳公司 | sGC活化剂和sGC刺激剂用于治疗认知障碍的用途 |
| CA3100096A1 (en) | 2018-05-15 | 2019-11-21 | Bayer Aktiengesellschaft | 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization |
| US11508483B2 (en) | 2018-05-30 | 2022-11-22 | Adverio Pharma Gmbh | Method of identifying a subgroup of patients suffering from dcSSc which benefits from a treatment with sGC stimulators and sGC activators in a higher degree than a control group |
| US20220128561A1 (en) | 2019-01-17 | 2022-04-28 | Bayer Aktiengesellschaft | Methods to determine whether a subject is suitable of being treated with an agonist of soluble gyanylyl cyclase (sgc) |
| EP4536205A1 (en) | 2022-06-09 | 2025-04-16 | Bayer Aktiengesellschaft | Soluble guanylate cyclase activators for use in the treatment of heart failure with preserved ejection fraction in women |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5602143A (en) | 1994-12-08 | 1997-02-11 | Allergan | Method for reducing intraocular pressure in the mammalian eye by administration of guanylate cyclase inhibitors |
| EP2091514B1 (en) * | 2006-11-09 | 2013-06-05 | Alcon Research, Ltd. | Water insoluble polymer matrix for drug delivery |
| WO2009071504A1 (en) * | 2007-12-03 | 2009-06-11 | Smithkline Beecham Corporation | 2,6-disubstituted pyridines as soluble guanylate cyclase activators |
| WO2010015653A1 (en) * | 2008-08-07 | 2010-02-11 | Smithkline Beecham Corporation | Pyrimidine derivatives as activators of soluble guanylate cyclase |
| MX2011008952A (es) | 2009-02-26 | 2011-09-27 | Merck Sharp & Dohme | Activadores de guanilato ciclasa solubles. |
| DE102009012314A1 (de) * | 2009-03-09 | 2010-09-16 | Bayer Schering Pharma Aktiengesellschaft | Oxo-heterocyclisch substituierte Alkylcarbonsäuren und ihre Verwendung |
| JP5636296B2 (ja) | 2011-01-20 | 2014-12-03 | 公益財団法人微生物化学研究会 | 塩分含有有機廃液処理剤、並びに、塩分濃度低下剤、塩分含有有機廃液の処理方法、及び包括固定担体 |
| JP6678656B2 (ja) * | 2014-09-19 | 2020-04-08 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | 新規な可溶性グアニル酸シクラーゼ活性剤およびそれらの使用 |
-
2015
- 2015-09-18 JP JP2017515074A patent/JP6678656B2/ja active Active
- 2015-09-18 CR CR20170102A patent/CR20170102A/es unknown
- 2015-09-18 BR BR112017005660A patent/BR112017005660A2/pt not_active Application Discontinuation
- 2015-09-18 MA MA040583A patent/MA40583A/fr unknown
- 2015-09-18 CN CN201580050717.XA patent/CN106687456B/zh active Active
- 2015-09-18 MX MX2017003621A patent/MX2017003621A/es unknown
- 2015-09-18 US US15/509,895 patent/US9938260B2/en active Active
- 2015-09-18 AU AU2015319724A patent/AU2015319724B2/en active Active
- 2015-09-18 EA EA201790655A patent/EA033697B1/ru not_active IP Right Cessation
- 2015-09-18 SG SG11201701915TA patent/SG11201701915TA/en unknown
- 2015-09-18 CA CA2961745A patent/CA2961745A1/en not_active Abandoned
- 2015-09-18 PE PE2017000478A patent/PE20170937A1/es unknown
- 2015-09-18 EP EP15772026.9A patent/EP3194384A1/en not_active Withdrawn
- 2015-09-18 KR KR1020177010181A patent/KR20170054508A/ko not_active Ceased
- 2015-09-18 WO PCT/IB2015/057219 patent/WO2016042536A1/en active Application Filing
-
2017
- 2017-03-12 IL IL251094A patent/IL251094A0/en unknown
- 2017-03-14 ZA ZA2017/01835A patent/ZA201701835B/en unknown
- 2017-03-14 PH PH12017500481A patent/PH12017500481A1/en unknown
- 2017-03-16 CL CL2017000640A patent/CL2017000640A1/es unknown
- 2017-03-16 CO CONC2017/0002506A patent/CO2017002506A2/es unknown
- 2017-03-16 DO DO2017000073A patent/DOP2017000073A/es unknown
-
2018
- 2018-03-05 US US15/911,797 patent/US10472350B2/en active Active
-
2020
- 2020-03-02 JP JP2020035272A patent/JP6908747B2/ja active Active
-
2021
- 2021-06-30 JP JP2021109106A patent/JP2021155450A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20180194756A1 (en) | 2018-07-12 |
| CN106687456B (zh) | 2019-12-03 |
| WO2016042536A1 (en) | 2016-03-24 |
| US20170305888A1 (en) | 2017-10-26 |
| AU2015319724A1 (en) | 2017-04-06 |
| EA201790655A1 (ru) | 2017-08-31 |
| ZA201701835B (en) | 2018-12-19 |
| CN106687456A (zh) | 2017-05-17 |
| JP6678656B2 (ja) | 2020-04-08 |
| JP2017527602A (ja) | 2017-09-21 |
| CR20170102A (es) | 2017-07-17 |
| US9938260B2 (en) | 2018-04-10 |
| PE20170937A1 (es) | 2017-07-13 |
| IL251094A0 (en) | 2017-04-30 |
| CL2017000640A1 (es) | 2017-10-06 |
| AU2015319724B2 (en) | 2018-05-10 |
| KR20170054508A (ko) | 2017-05-17 |
| EP3194384A1 (en) | 2017-07-26 |
| BR112017005660A2 (pt) | 2017-12-19 |
| DOP2017000073A (es) | 2017-04-16 |
| PH12017500481A1 (en) | 2017-08-07 |
| EA033697B1 (ru) | 2019-11-18 |
| JP2020105189A (ja) | 2020-07-09 |
| JP6908747B2 (ja) | 2021-07-28 |
| MA40583A (fr) | 2016-03-24 |
| JP2021155450A (ja) | 2021-10-07 |
| MX2017003621A (es) | 2017-07-14 |
| CA2961745A1 (en) | 2016-03-24 |
| US10472350B2 (en) | 2019-11-12 |
| SG11201701915TA (en) | 2017-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2017002506A2 (es) | Nuevos activadores de la guanilato ciclasa soluble y su uso | |
| ECSP17078433A (es) | Composiciones de ácido obeticólico y métodos de uso | |
| DOP2019000005A (es) | 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2 | |
| NI201700096A (es) | Derivados de 4h-pirrol[3, 2-c]piridin-4-ona | |
| CY1123953T1 (el) | Καθυστερημενης απελευθερωσης συνθεσεις λινακλοτιδης | |
| SV2018005610A (es) | Derivados de oxopiridina sustituidos | |
| ECSP17081744A (es) | Nuevos derivados hidroxiéster,un proceso para su preparación y composiciones farmacéuticas que los contienen | |
| CL2017001923A1 (es) | Derivados de 9h-pirrolo-dipiridina | |
| ECSP18074962A (es) | Derivados de aminotiazol útiles como agentes antivíricos | |
| ECSP16074478A (es) | Compuestos novedosos | |
| MX2017013875A (es) | Ciertos inhibidores de la proteína quinasa. | |
| AR101414A1 (es) | Derivados de pirrolidinona como inhibidores de metap-2 | |
| DOP2016000297A (es) | Composiciones farmacéuticas útiles para tratar enfermedades infecciosas | |
| MX2017013137A (es) | Derivados de cromeno como inhibidores de las fosfoinositido-3-cina sas. | |
| UY35997A (es) | Derivados de isoquinoleína, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| CO2019008110A2 (es) | Activador de nrf2 | |
| CO2018012020A2 (es) | Derivados de piridinilo, composiciones farmacéuticas y sus usos como inhibidores aoc3 | |
| MX2018005987A (es) | Compuestos heterociclicos para el tratamiento de enfermedades. | |
| CO2017002963A2 (es) | Espiro-tiazolonas | |
| CR20140051A (es) | Compuestos de tiazol y oxazol de bencen-sulfonamida | |
| UY36958A (es) | Compuestos para administración intracelular | |
| MX385113B (es) | Uso de hidróxido de potasio en el tratamiento de la queratosis actínica. |